Cargando…
The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression
Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic nephropathy, is characterized by phenotypic variability that exceeds genic effects. Dysregulated metabolism and immune cell function are key disease modifiers. The tryptophan metabolites, kynurenines, produced through in...
Autores principales: | Nguyen, Dustin T., Kleczko, Emily K., Dwivedi, Nidhi, Monaghan, Marie-Louise T., Gitomer, Berenice Y., Chonchol, Michel B., Clambey, Eric T., Nemenoff, Raphael A., Klawitter, Jelena, Hopp, Katharina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870090/ https://www.ncbi.nlm.nih.gov/pubmed/36422996 http://dx.doi.org/10.1172/jci.insight.154773 |
Ejemplares similares
-
Immune checkpoint activity regulates polycystic kidney disease progression
por: Kleczko, Emily K., et al.
Publicado: (2023) -
Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease
por: Baliga, Madhurima M., et al.
Publicado: (2021) -
CD8(+) T cells modulate autosomal dominant polycystic kidney disease progression
por: Kleczko, Emily K., et al.
Publicado: (2018) -
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
por: Brochez, Lieve, et al.
Publicado: (2021) -
A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases
por: Zhou, Qihui, et al.
Publicado: (2021)